Jan 27, 2025, 09:51
Petros Grivas: Neoadjuvant Cisplatin-Based Chemotherapy + Peri-Operative Durvalumab as SOC in Fit Patients with MIBC
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, shared a post on X:
“Discussion dynamic AUC3 meeting: while I wouldn’t advocate for a trial comparing GC vs ddMVAC (waste of resources/time), I support the guideline of neoadjuvant ‘cisplatin based chemo’ + peri-op durvalumab as SOC in fit patients with MIBC based on NIAGARA and other trials.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 28, 2025, 18:34
Feb 28, 2025, 15:34
Feb 28, 2025, 15:33
Feb 28, 2025, 15:25
Feb 28, 2025, 15:22
Feb 28, 2025, 15:20
Feb 28, 2025, 15:13
Feb 28, 2025, 15:02
Feb 28, 2025, 14:43
Feb 28, 2025, 14:37